Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Vonoprazan-based Quadruple Therapy for H. pylori
NCT02892409Phase 1Completed
- Sponsor
- Takeda
- Start
- Sep 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vonoprazan in Helicobacter pylori infection (2 arms), sponsored by Takeda. Primary endpoints: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event at Day 17, Percentage of Participants Who Discontinue Due to an Adverse Event at Day 17 and 6 more. Started Sep 2016; status: completed.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT02892409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02892409.